SPECIALTY CARE 
Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023
Updated: 07/16/24
In this MCT2D-led paper, published in JAMA in May 2024, researchers investigated changes in GLP-1RA prescribing rates to U.S. adolescents and young adult patients between 2020 and 2023. They found a dramatic increase in the number of people receiving these medications, with a nearly 600% rise. This increase was especially significant for females.
The work was led by Joyce M. Lee, MD, MPH, MCT2D content expert and the Robert P. Kelch Research Professor of Pediatrics, Division of Pediatric Endocrinology, at the University of Michigan. Additional authors included MCT2D Director, Lauren Oshman, MD, MPH, and MCT2D content expert and obesity medicine specialist, Dina Hafez Griauzde, MD.
Citation: Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua K-P. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023. JAMA. Published online May 22, 2024. doi:10.1001/jama.2024.7112
Tags: For Providers, Research, Created By MCT2D
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.